Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Perrigo's abbreviated new drug application for Ketoconazole Foam, 2%.
Subscribe to our email newsletter
Perrigo’s Ketoconazole Foam, 2% is generic equivalent to Extina Ketoconazole Foam, 2%.
Ketoconazole Foam, 2% is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
Perrigo chairman and CEO Joseph Papa said this launch reflects their continuing investment in new products.
"It is an example of the excellent partnership we have with Cobrek for developing foam products which is a key product category for our Rx business," Papa said.